Sage Journals: Discover world-class research

Abstract

Background

Systemic examination for distant metastases is generally recommended for all lung cancer patients. However, this approach rarely detects distant metastases in typically resectable cT1-2N0 non-small-cell lung cancer. The aim of this study was to identify factors associated with distant metastases and develop indication criteria for preoperative systemic examination in patients with cT1-2N0 non-small-cell lung cancer, with a particular focus on computed tomography imaging of primary lesions.

Methods

We retrospectively reviewed non-small-cell lung cancer patients treated at our institute between 2005 and 2013. Data were extracted and compared between two groups: patients diagnosed as cT1-2N0M0 who underwent complete resection (M0 group, n = 1530) and those diagnosed as cT1-2N0M1b who received systemic chemotherapy (M1 group, n = 26).

Results

The median age at diagnosis was significantly lower in the M1 group (p = 0.015). Although carcinoembryonic antigen levels were significantly higher in the M1 group (p < 0.001), 42% had normal levels. Tumor diameters in lung and mediastinal windows on chest computed tomography were significantly larger, and the proportion (mediastinal/lung window tumor diameter ratio) was higher in the M1 group (p < 0.001). All 26 patients in the M1 group had a tumor diameter >15 mm and mediastinal/lung window ratio >0.75.

Conclusions

Preoperative systemic examination is not necessary in cT1-2N0 non-small-cell lung cancer patients when tumor diameters are ≤15 mm and mediastinal/lung window ratios are ≤0.75. According to these criteria, systemic examinations would have been reduced by 40% in our cohort.

Keywords

Carcinoma non-small-cell lung Lymphatic metastasis Neoplasm staging Tomography X-ray computed

Get full access to this article

View all access options for this article.

References

Siegel

Naishadham

Jemal

. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11–30.

Lynch

Bell

Sordella

. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129–2139.

Paez

Jänne

Lee

. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497–1500.

Soda

Choi

Enomoto

Takada

. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561–566.

Mitsudomi

Morita

Yatabe

. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121–128.

Silvestri

Gonzalez

Jantz

. Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2013; 143: e211S–50S.

National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Available at: www.nccn.org. Accessed December 16, 2014.

Tumours of the lung. In: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Travis WD, Brambilla E, Muller-Hermelink HK, editors. Lyon, France: IASLC Press, 2004:9–122.

Travis

Brambilla

Noguchi

. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011; 6: 244–285.

10.

Goldstraw

. Staging Manual in Thoracic Oncology, Denver, CO: IASLC, 2009, pp. 92–109.

11.

International Union Against Cancer. Sobin LH, G.M., Wittekind CH, TNM Classification of Malignant Tumours, 7th ed. New York, NY: Wiley-Liss, 2009, pp. 136–146.

12.

General Rule for Clinical and Pathological Record of Lung Cancer. 7th ed. TJLC Society. Tokyo, Japan: Kanehara & Co. Ltd., 2010.

13.

Suzuki

Koike

Asakawa

. A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). J Thorac Oncol 2011; 6: 751–756.

14.

Okada

Nakayama

Okumura

. Multicenter analysis of high-resolution computed tomography and positron emission tomography/computed tomography findings to choose therapeutic strategies for clinical stage IA lung adenocarcinoma. J Thorac Cardiovasc Surg 2011; 141: 1384–1391.

15.

Nakao

Yoshida

Goto

. Long-term outcomes of 50 cases of limited-resection trial for pulmonary ground-glass opacity nodules. J Thorac Oncol 2012; 7: 1563–1566.

16.

Pieterman

van Putten

Meuzelaar

. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000; 343: 254–261.

17.

van Tinteren

Hoekstra

Smit

. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002; 359: 1388–1393.

18.

Gould

Maclean

Kuschner

Rydzak

Owens

. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 2001; 285: 914–924.

19.

Higashi

Ueda

Seki

. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998; 39: 1016–1020.

20.

Kim

Park

Goo

Lee

. Is there a role for FDG PET in the management of lung cancer manifesting predominantly as ground-glass opacity? AJR Am J Roentgenol 2012; 198: 83–88.